185 related articles for article (PubMed ID: 35886531)
1. Early Complications and Results of Preserflo MicroShunt in the Management of Uncontrolled Open-Angle Glaucoma: A Case Series.
Saeed E; Zalewska R; Konopińska J
Int J Environ Res Public Health; 2022 Jul; 19(14):. PubMed ID: 35886531
[TBL] [Abstract][Full Text] [Related]
2. Safety and Effectiveness of the PRESERFLO® MicroShunt in Primary Open-Angle Glaucoma: Results from a 2-Year Multicenter Study.
Beckers HJM; Aptel F; Webers CAB; Bluwol E; Martínez-de-la-Casa JM; García-Feijoó J; Lachkar Y; Méndez-Hernández CD; Riss I; Shao H; Pinchuk L; Angeles R; Sadruddin O; Shaarawy TM
Ophthalmol Glaucoma; 2022; 5(2):195-209. PubMed ID: 34329772
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of Open Bleb Revision After PreserFlo MicroShunt Failure in Patients With Glaucoma.
Strzalkowska A; Strzalkowski P; Hoffmann EM; Pfeiffer N; Schuster AK
J Glaucoma; 2023 Aug; 32(8):681-685. PubMed ID: 37327469
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of MicroShunt in Patients with Primary Open-Angle and Pseudoexfoliative Glaucoma: A Retrospective European Multicenter Study.
Fea AM; Laffi GL; Martini E; Economou MA; Caselgrandi P; Sacchi M; Au L
Ophthalmol Glaucoma; 2022; 5(2):210-218. PubMed ID: 34478904
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of the Preserflo Microshunt With Mitomycin C for the Treatment of Open Angle Glaucoma.
Ibarz Barberá M; Martínez-Galdón F; Caballero-Magro E; Rodríguez-Piñero M; Tañá-Rivero P
J Glaucoma; 2022 Jul; 31(7):557-566. PubMed ID: 35583510
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of PreserFlo
Quaranta L; Micheletti E; Carassa R; Bruttini C; Fausto R; Katsanos A; Riva I
Adv Ther; 2021 Aug; 38(8):4403-4412. PubMed ID: 34251652
[TBL] [Abstract][Full Text] [Related]
7. Ab-Externo MicroShunt versus Trabeculectomy in Primary Open-Angle Glaucoma: One-Year Results from a 2-Year Randomized, Multicenter Study.
Baker ND; Barnebey HS; Moster MR; Stiles MC; Vold SD; Khatana AK; Flowers BE; Grover DS; Strouthidis NG; Panarelli JF;
Ophthalmology; 2021 Dec; 128(12):1710-1721. PubMed ID: 34051211
[TBL] [Abstract][Full Text] [Related]
8. Clinical Outcomes and Cost Analysis of PreserFlo versus Trabeculectomy for Glaucoma Management in the United Kingdom.
Van Lancker L; Saravanan A; Abu-Bakra M; Reid K; Quijano C; Goyal S; Rodrigues I; Lascaratos G; Trikha S; Barwood C; Combe E; Kulkarni A; Lim KS; Low S
Ophthalmol Glaucoma; 2023; 6(4):342-357. PubMed ID: 36427750
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Bevacizumab Compared to Mitomycin C Modulated Trabeculectomy in Primary Open Angle Glaucoma: A One-Year Prospective Randomized Controlled Study.
Kaushik J; Parihar JK; Jain VK; Gupta S; Nath P; Durgapal P; Ram J
Curr Eye Res; 2017 Feb; 42(2):217-224. PubMed ID: 27269279
[TBL] [Abstract][Full Text] [Related]
10. Intermediate Outcomes of a Novel Standalone Ab Externo SIBS Microshunt With Mitomycin C.
Schlenker MB; Durr GM; Michaelov E; Ahmed IIK
Am J Ophthalmol; 2020 Jul; 215():141-153. PubMed ID: 32173344
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of the PreserFlo implant with mitomycin C in childhood glaucoma after previous failed glaucoma surgeries.
Burgos-Blasco B; García-Feijóo J; Gines-Gallego C; Perucho-Gonzalez L; Fernandez-Vigo JI; Martinez de la Casa JM; Saenz-Frances F; Morales-Fernandez L; Mendez-Hernandez CD
Graefes Arch Clin Exp Ophthalmol; 2023 May; 261(5):1349-1357. PubMed ID: 36536223
[TBL] [Abstract][Full Text] [Related]
12. The PreserFlo MicroShunt in the Context of Minimally Invasive Glaucoma Surgery: A Narrative Review.
Saeed E; Gołaszewska K; Dmuchowska DA; Zalewska R; Konopińska J
Int J Environ Res Public Health; 2023 Feb; 20(4):. PubMed ID: 36833599
[TBL] [Abstract][Full Text] [Related]
13. Intraoperative primary partial occlusion of the PreserFlo MicroShunt to prevent initial postoperative hypotony.
Lüke JN; Reinking N; Dietlein TS; Haendel A; Enders P; Lappas A
Int Ophthalmol; 2023 Aug; 43(8):2643-2651. PubMed ID: 36905460
[TBL] [Abstract][Full Text] [Related]
14. Preserflo microshunt implant for the treatment of refractory uveitic glaucoma: 36-month outcomes.
Triolo G; Wang J; Aguilar-Munoa S; Jayaram H; Barton K
Eye (Lond); 2023 Aug; 37(12):2535-2541. PubMed ID: 36577805
[TBL] [Abstract][Full Text] [Related]
15. Blood Reflux Through a PreserFlo MicroShunt Device After Needling.
Cassottana P; Di Mola I; Ferro Desideri L; Vagge A; Cutolo CA; Traverso CE; Iester M
J Glaucoma; 2022 Dec; 31(12):979-981. PubMed ID: 35939834
[TBL] [Abstract][Full Text] [Related]
16. One Year Results of the Preserflo MicroShunt Implantation for Refractory Glaucoma.
Seuthe AM; Erokhina M; Szurman P; Haus A
J Glaucoma; 2023 May; 32(5):414-419. PubMed ID: 36795529
[TBL] [Abstract][Full Text] [Related]
17. Long-term Results of the PRESERFLO MicroShunt in Patients With Primary Open-angle Glaucoma From a Single-center Nonrandomized Study.
Batlle JF; Corona A; Albuquerque R
J Glaucoma; 2021 Mar; 30(3):281-286. PubMed ID: 33137019
[TBL] [Abstract][Full Text] [Related]
18. XEN
Scheres LMJ; Kujovic-Aleksov S; Ramdas WD; de Crom RMPC; Roelofs LCG; Berendschot TTJM; Webers CAB; Beckers HJM
Acta Ophthalmol; 2021 May; 99(3):e433-e440. PubMed ID: 32909682
[TBL] [Abstract][Full Text] [Related]
19. One-year surgical outcomes of the PreserFlo MicroShunt in glaucoma: a multicentre analysis.
Tanner A; Haddad F; Fajardo-Sanchez J; Nguyen E; Thong KX; Ah-Moye S; Perl N; Abu-Bakra M; Kulkarni A; Trikha S; Lascaratos G; Parnell M; Kailani O; King AJ; Agrawal P; Stead R; Giannouladis K; Rodrigues I; Goyal S; Hysi PG; Lim S; Yu-Wai-Man C
Br J Ophthalmol; 2023 Aug; 107(8):1104-1111. PubMed ID: 35365491
[TBL] [Abstract][Full Text] [Related]
20. PreserFlo™ MicroShunt Versus Trabeculectomy in Patients With Moderate to Advanced Open-Angle Glaucoma: 12-Month Follow-Up of a Single-Center Prospective Study.
Fili S; Kontopoulou K; Vastardis I; Perdikakis G; Kohlhaas M
Cureus; 2022 Aug; 14(8):e28288. PubMed ID: 36158358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
